Extraocular features of Leber hereditary optic neuropathy: A scoping review
Journal of Biological Methods · 14.05.2025 · 12 (2) · e99010055
DOI: 10.14440/jbm.2024.0113 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biological Methods, online erschienen am 14.05.2025. Verfasst von Layla Ali und 8 weiteren Autor:innen. Beteiligte Einrichtung: Office of Research, College of Medicine, California Northstate University, Elk Grove, California 95757, United States of America. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Leber hereditary optic neuropathy (LHON) is a rare inherited mitochondrial disease that leads to mitochondrial dysfunction, resulting in optic nerve damage and vision loss. Systemic involvement has been reported in several LHON cases, referred to as LHON+ disorders. However, the causes and presentations of such conditions have been poorly studied. It is suggested that 90% of mitochondrial dysfunction is caused by one of three primary point mutations in mitochondrial DNA that affect respiratory complex I (referred to as mtDNA LHON), with unresolved cases of LHON being caused by other variants, known as autosomal recessive LHON. The cardiac, musculoskeletal, neurological, and auditory systems are commonly affected in LHON. For example, hypertrophic cardiomyopathy and sudden cardiac death have been linked to specific mutations. Neurological effects – such as dystonia, epilepsy, polyneuropathy, and ataxia – as well as hearing loss, have also been observed in patients with specific mitochondrial mutations. These findings highlight the need for a more comprehensive evaluation beyond standard ophthalmic assessments. LHON is typically diagnosed based on a combination of ophthalmic imaging, patient age and gender, clinical course (bilateral, rapidly progressive, and sequential visual loss), family history, maternal inheritance, and fundus appearance. However, the advent of genetic testing has significantly expanded the recognized phenotype. In terms of treatment, idebenone is the only FDA-approved therapy for LHON; however, intravitreal gene therapy yields promising improvement, especially for the most common m.11778G>A mutation, which accounts for 70% of causative mutations. At present, these therapies are confined to ocular treatment.
Objective
This review highlights the importance of recognizing systemic manifestations of LHON, which are frequently overlooked in clinical practice.
Conclusion
Early detection of these systemic manifestations, especially in cardiac and neurological systems, could help with prompt intervention and improve patient outcomes. Further research into gene therapy and mitochondrial replacement techniques holds promising potential for developing more effective treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Office of Research, College of Medicine, California Northstate University, Elk Grove, California 95757, United States of America.
- Department of Translational Science, Rush University Medical Center, Chicago, Illinois 60612, United States of America.
Zitieren
APA
Ali, L., Hazzard, I., Tehrani, N. S., Ansari, U., Ali, A., Kumar, P., Ali, N., Gakhal, G., & Lui, F. (2025). Extraocular features of Leber hereditary optic neuropathy: A scoping review. Journal of Biological Methods, 12(2), e99010055. https://doi.org/10.14440/jbm.2024.0113
Vancouver
Ali L, Hazzard I, Tehrani NS, Ansari U, Ali A, Kumar P, et al. Extraocular features of Leber hereditary optic neuropathy: A scoping review. Journal of Biological Methods. 2025;12(2):e99010055. doi:10.14440/jbm.2024.0113
BibTeX
@article{Ali2025,
author = {Ali, Layla and Hazzard, Iyawnna and Tehrani, Niloufar S and Ansari, Ubaid and Ali, Adam and Kumar, Preyasi and Ali, Nadia and Gakhal, Gurkiranjeet and Lui, Forshing},
title = {Extraocular features of Leber hereditary optic neuropathy: A scoping review},
journal = {Journal of Biological Methods},
year = {2025},
volume = {12},
number = {2},
pages = {e99010055},
doi = {10.14440/jbm.2024.0113}
}
EUVIMED